From: [redacted] (SANTE)
Sent: jeudi 14 novembre 2019 15:12
To: [redacted] (SANTE); [redacted] (SANTE); [redacted] (SANTE); [redacted] (SANTE); [redacted] (SANTE); [redacted] (SANTE); [redacted] (SANTE); [redacted] (SANTE); [redacted] (SANTE); [redacted] (SANTE)
Cc: [redacted] (SANTE); [redacted] (SANTE); [redacted] (SANTE)
Subject: BTO BASF meeting 21.10.19

BTO: DG SANTE-BASF meeting

21 October 2019

Participants:
- *- SANTE (E3):* [redacted]
- *- BASF:* [redacted] *Regulatory & Stewardship Seeds & Traits),* [redacted] *Innovation & Technology Policy, EU Goverment Relations),* [redacted] *(EMEA regulatory team seeds)*

The meeting took place at DG SANTE premises following a request from BASF.

- BASF
  - discussed the status of pending GMO applications;
  - shared their views on the impacts of the CJEU ruling on mutagenesis;
  - asked the Commission if it intends to take any initiative following the CJEU ruling;
  - inquired about the impact of the new General Food Law (Transparency Regulation) for the submission of applications and risk communication.

- DG SANTE stated that
  - the CJEU ruling must be implemented;
  - there are no plans for any initiative on gene editing under this College of Commissioners;
  - the new GFL enters into force in March 2021 and clarifications will be channelled through EuropaBio if needed.